Annals of Oncology

1

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Mosele, F., Stefanovska, B., Lusque, A., Tran Dien, A., Garberis, I., Droin, N., Le Tourneau, C., Sablin, M.-P., Lacroix, L., Enrico, D., Miran, I., Jovelet, C., BiÃ¨che, I., Soria, J.-C., Bertucci, F

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 431 KB

english, 2020

2

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light,Â and heavy smokers with non-small-cell lung cancer and PD-L1 expression â¥50%

Gainor, J.F., Rizvi, H., Jimenez Aguilar, E., Skoulidis, F., Yeap, B.Y., Naidoo, J., Khosrowjerdi, S., Mooradian, M., Lydon, C., Illei, P., Zhang, J., Peterson, R., Ricciuti, B., Nishino, M., Zhang, J

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 3.17 MB

english, 2020

3

Interpreting the impact of apalutamide on overall survival among patients with non-metastatic castration-resistant prostate cancer

McCaw, Z.R., Wei, L.-J., Ludmir, E.B.

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 963 KB

english, 2020

4

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOSâESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Chen, L.-T., Martinelli, E., Cheng, A.-L., Pentheroudakis, G., Qin, S., Bhattacharyya, G.S., Ikeda, M., Lim, H.-Y., Ho, G.F., Choo, S.P., Ren, Z., Malhotra, H., Ueno, M., Ryoo, B.-Y., Kiang, T.C., Tai

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 579 KB

english, 2020

5

High-risk neuroblastoma: where do we go?

CaÃ±ete, A.

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 154 KB

english, 2020

6

A systematic review and meta-analysis of the 2007 WCRF/AICR score in relation to cancer-related health outcomes

Solans, M., Chan, D.S.M., Mitrou, P., Norat, T., Romaguera, D.

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 691 KB

english, 2020

7

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research GroupÂ (HORG)

Mavroudis, D., Saloustros, E., Malamos, N., Kakolyris, S., Boukovinas, I., Papakotoulas, P., Kentepozidis, N., Ziras, N., Georgoulias, V.

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 154 KB

english, 2020

8

From astrology to prostate cancer: what is the role of subgroup analyses?

Messina, C., Messina, M., Cattrini, C.

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 508 KB

english, 2020

9

Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure

Alyamani, M., Li, J., Patel, M., Taylor, S., Nakamura, F., Berk, M., Przybycin, C., Posadas, E.M., Madan, R.A., Gulley, J.L., Rini, B., Garcia, J.A., Klein, E.A., Sharifi, N.

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 1.33 MB

english, 2020

10

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

Clarke, N.W., Ali, A., Ingleby, F.C., Hoyle, A., Amos, C.L., Attard, G., Brawley, C.D., Calvert, J., Chowdhury, S., Cook, A., Cross, W., Dearnaley, D.P., Douis, H., Gilbert, D., Gillessen, S., Jones,

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 129 KB

english, 2020

11

Glucocorticoids mediate adverse events of deep androgen receptor axis inhibition in prostate cancer patients

Kaochar, S., Mitsiades, N.

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 364 KB

english, 2020

12

The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers

Yver, A., Agatsuma, T., Soria, J.-C.

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 245 KB

english, 2020

13

Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study

Kurzrock, R., Bowles, D.W., Kang, H., Meric-Bernstam, F., Hainsworth, J., Spigel, D.R., Bose, R., Burris, H., Sweeney, C.J., Beattie, M.S., Blotner, S., Schulze, K., Cuchelkar, V., Swanton, C.

Journal:

Annals of Oncology

Year:

2020

File:

PDF, 2.08 MB

2020

14

Primary tumor somatic mutations in the blood of women with ductal carcinoma in situ of the breast

Di Cosimo, S., Appierto, V., Silvestri, M., Ortolan, E., De Cecco, L., Veneroni, S., Pruneri, G., Vingiani, A., Belfiore, A., Scaperrotta, G., Folli, S., Daidone, M.G.

Journal:

Annals of Oncology

Year:

2020

File:

PDF, 580 KB

2020

15

Flawed trials for cancer

Tannock, I.F., Templeton, A.J.

Journal:

Annals of Oncology

Year:

2020

File:

PDF, 163 KB

2020

16

When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, aÂ RETÂ inhibitor

Gill, J., Prasad, V.

Journal:

Annals of Oncology

Year:

2020

File:

PDF, 154 KB

2020

17

Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR

Berthold, F., Faldum, A., Ernst, A., Boos, J., Dilloo, D., Eggert, A., Fischer, M., FrÃ¼hwald, M., Henze, G., Klingebiel, T., Kratz, C., Kremens, B., Krug, B., Leuschner, I., Schmidt, M., Schmidt, R.,

Journal:

Annals of Oncology

Year:

2020

Language:

english

File:

PDF, 1.31 MB

english, 2020

18

Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification

Mazzotta, M., Filetti, M., Rossi, A., Roberto, M., Occhipinti, M., Pernazza, A., Di Napoli, A., Scarpino, S., Vecchione, A., Giusti, R., Marchetti, P.

Journal:

Annals of Oncology

Year:

2020

File:

PDF, 801 KB

2020

19

Corrigendum to Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark

Boysen, A.K., Andersen, I.T., Acquavella, J., Seesaghur, A.M., Hernandez, R.K., Ehrenstein, V.

Journal:

Annals of Oncology

Year:

2020

File:

PDF, 104 KB

2020

20

Volume 31; Issue 3

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light,Â and heavy smokers with non-small-cell lung cancer and PD-L1 expression â¥50%

Interpreting the impact of apalutamide on overall survival among patients with non-metastatic castration-resistant prostate cancer

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOSâESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

High-risk neuroblastoma: where do we go?

A systematic review and meta-analysis of the 2007 WCRF/AICR score in relation to cancer-related health outcomes

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research GroupÂ (HORG)

From astrology to prostate cancer: what is the role of subgroup analyses?

Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

Glucocorticoids mediate adverse events of deep androgen receptor axis inhibition in prostate cancer patients

The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers

Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study

Primary tumor somatic mutations in the blood of women with ductal carcinoma in situ of the breast

Flawed trials for cancer

When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, aÂ RETÂ inhibitor

Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR

Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification

Corrigendum to Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark

Table of Contents